English
Regional settings| Spread | 0.07 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 5.22 |
| Open | 5.25 |
| 1-Year Change | -20.21% |
| Day's Range | 5.24 - 5.33 |
OraSure Technologies, Inc. (OraSure) is a medical device company that develops, manufactures, and markets medical devices and diagnostic products. The Company's products include molecular sampling kits for the genome and microbiome services and analytics, rapid diagnostics for infectious disease, and tests for substance abuse. OraSure’s segments include Diagnostics segment and Molecular Collection Systems segment. The Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices. The Molecular Solutions business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbiome and animal genetics markets.
BRIEF: For the fiscal year ended 31 December 2021, OraSure Technologies, Inc. revenues increased 36% to $233.7M. Net loss increased 54% to $23M. Revenues reflect Molecular Solutions segment increase of 35% to $143.6M, Diagnostics segment increase of 38% to $90M, United States segment increase of 44% to $188.4M, Other Regions segment increase of 9% to $31.5M, Europe segment increase of 14% to $13.8M.
Common Stock $.000001 Par, 03/11, 120M auth., 46,626,324 o/s. Insiders own 2.05%. 9/29/00, Company formed through pooling between Epitope and OraSure Technologies.
